quinapril has been researched along with moexipril in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blankley, CJ; Cohen, DM; Essenburg, AD; Fleming, RW; Hinkley, JM; Hoefle, ML; Holmes, A; Klutchko, S; Nordin, I; Werner, AE | 1 |
| Abbenante, G; Fairlie, DP; Leung, D | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Sun, H | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bicket, DP | 1 |
| Berti, F; Cella, SG; Locatelli, V; Sanguini, AM; Torsello, A | 1 |
3 review(s) available for quinapril and moexipril
| Article | Year |
|---|---|
Protease inhibitors: current status and future prospects.
Topics: Animals; Aspartic Acid Endopeptidases; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Humans; Metalloendopeptidases; Models, Molecular; Protease Inhibitors; Serine Endopeptidases; Serine Proteinase Inhibitors | 2000 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Using ACE inhibitors appropriately.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Captopril; Cardiovascular Diseases; Clinical Trials as Topic; Contraindications; Diabetic Nephropathies; Drug Costs; Enalapril; Fosinopril; Heart Failure; Humans; Hypertension; Indoles; Isoquinolines; Lisinopril; Meta-Analysis as Topic; Myocardial Infarction; Perindopril; Quinapril; Ramipril; Renin-Angiotensin System; Risk; Tetrahydroisoquinolines; United States | 2002 |
5 other study(ies) available for quinapril and moexipril
| Article | Year |
|---|---|
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Isoquinolines; Male; Molecular Conformation; Quinapril; Rats; Rats, Inbred Strains; Structure-Activity Relationship; Sulfhydryl Compounds; Tetrahydroisoquinolines | 1986 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
Topics: Carboxylic Acids; Cytochrome P-450 Enzyme System; Esters; Humans; Hydrolysis; Microsomes; Models, Molecular; Molecular Structure; Prodrugs; Quantum Theory; Signal Transduction | 2012 |
Moexipril and quinapril inhibition of tissue angiotensin-converting enzyme activity in the rat: evidence for direct effects in heart, lung and kidney and stimulation of prostacyclin generation.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Drug Administration Schedule; Epoprostenol; Heart; In Vitro Techniques; Isoquinolines; Kidney; Lung; Male; Peptidyl-Dipeptidase A; Quinapril; Rats; Rats, Sprague-Dawley; Tetrahydroisoquinolines | 2003 |